Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial

AIMS: The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial assessed once-weekly exenatide (EQW) vs. placebo, added to usual care in 14,752 patients with type 2 diabetes mellitus (Clinicaltrials.gov: NCT01144338). We assessed the lifetime cost-effectiveness of adding EQW vs. usual care...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Frauke, Dakin, Helen A., Reed, Shelby D., Li, Yanhong, Leal, José, Gustavson, Stephanie M., Wittbrodt, Eric, Hernandez, Adrian F., Gray, Alastair M., Holman, Rury R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Scientific Publishers 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844554/
https://www.ncbi.nlm.nih.gov/pubmed/34813910
http://dx.doi.org/10.1016/j.diabres.2021.109152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844554/
https://www.ncbi.nlm.nih.gov/pubmed/34813910
http://dx.doi.org/10.1016/j.diabres.2021.109152

Ejemplares similares